PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

Summary

This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.

Timeline

Start

2021-05-26

Primary completion

2024-12

Completion

2025-12

Publications

• Wang Y, Jia R, Si H, Ma Y, Fan M, Zhang N, Liu F, Shi Y, Jia Y, Zhang Y, Han Q, Wang Z, Dai G. Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer. BMC Cancer. 2025 Mar 7;25(1):422. doi: 10.1186/s12885-025-13794-w.

Drugs

Indications